8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 19, 2026·SEC
Material company update
May 7, 2026·SEC
InMed Pharmaceuticals Inc.(INM)Earnings, Financials & Key Ratios
INM•NASDAQ
$1.67
Price updated Jul 7, 2026
AboutInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Show more
- Revenue$5M+7.5%
- EBITDA-$7M+1.9%
- Net Income-$8M-6.3%
- EPS (Diluted)-8.36+58.5%
- Gross Margin34.53%+44.2%
- EBITDA Margin-149.38%+8.8%
- Operating Margin-160.2%+9.5%
- Net Margin-165.14%+1.1%
- ROE-52.84%+1.5%
INM Price & Volume
InMed Pharmaceuticals Inc. (INM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Burn Masks Structural Revenue Volatility
Investment Thesis • Updated 2026Q3
VerdictNegative: The company's persistent negative operating margins
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Persistent capital dilution risk
Key Thesis Takeaways
- InMed Pharmaceuticals faces a challenging fundamental outlook characterized by persistent operating losses and a reliance on non-recurring revenue spikes, such as the $659.8 million reported in 2026Q3.
- The company's inability to achieve consistent profitability, evidenced by a $124.0 million accumulated deficit, suggests significant long-term execution risk.
- Investors should monitor the rapid depletion of liquid assets, which fell to $5.2 million in 2026Q3, as the firm continues to navigate structural disconnects between administrative overhead and commercial output.
Verdict Logic
which reached -160.20% in recent periods, combined with a dwindling cash position of $5.2 million, suggest a high probability of future dilutive equity raises.
INM Growth Metrics
InMed Pharmaceuticals Inc. (INM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years65.55%
TTM13390.59%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-19.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-8939.08%
Return on Capital
10 Years-92.55%
5 Years-89.78%
3 Years-54.56%
Last Year-49.19%
Peers Comparison
Key metrics vs top competitors for InMed Pharmaceuticals Inc. (INM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.67 | $3.02M | -0.20 | 7.5% | -165.14% | -52.84% | — | |
| $0.74 | $7.75M | -0.68 | -1.5% | -13.29% | -33.59% | — | |
| $5.19 | $1.91B | -1.78 | 1227.6% | -19019.44% | -366.21% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $1.30 | $336.96M | -30.79 | 2.82% | -1.17% | -1% | — | |
| $9.38 | $117.58M | -1.59 | — | — | -70.89% | — |
Compare INM vs Peers
InMed Pharmaceuticals Inc. (INM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INM SEC Filings & Documents
InMed Pharmaceuticals Inc. (INM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INM Frequently Asked Questions
InMed Pharmaceuticals Inc. (INM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is InMed Pharmaceuticals Inc.'s revenue?
InMed Pharmaceuticals Inc. (INM) reported $663.9M in revenue for fiscal year 2025. This represents a 27185432% increase from $0.0M in 2001.
How fast is InMed Pharmaceuticals Inc. growing?
InMed Pharmaceuticals Inc. (INM) grew revenue by 7.5% over the past year. This is steady growth.
Is INM profitable?
InMed Pharmaceuticals Inc. (INM) reported a net loss of $9.9M for fiscal year 2025.
Dividend & Returns
What is INM's return on equity?
InMed Pharmaceuticals Inc. (INM) has a return on equity (ROE) of -52.8%. Negative ROE indicates the company is unprofitable.
What is InMed Pharmaceuticals Inc.'s free cash flow?
InMed Pharmaceuticals Inc. (INM) had negative free cash flow of $9.0M in fiscal year 2025, likely due to heavy capital investments.